Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 5/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | CDC25B | P30305 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | S100A4 | P26447 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 3/20 | 0.52 |
| ▸ | ATG4B | Q9Y4P1 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29390818 | 1.00 | PTPRC (0.55) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL3894758 | 0.98 | MEN1 (0.57) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL13487409 | 0.95 | PTPRC (0.60) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL30886642 | 0.95 | PTPRC (0.60) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL563010 | 0.95 | MEN1 (0.55) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL13487417 | 0.91 | PTPRC (0.59) | PTPRCPTPN1MEN1KMT2ACDC25B | |
| SCHEMBL9811010 | 0.91 | CA1 (0.48) | PTPRCPTPN1NPC1RAB9AALDH1A1 | |
| SCHEMBL30479662 | 0.91 | CA1 (0.52) | PTPRCPTPN1ALDH1A1CYP3A4S100A4 | |
| SCHEMBL7432075 | 0.91 | CA1 (0.52) | PTPRCPTPN1ALDH1A1CYP3A4S100A4 | |
| SCHEMBL9328908 | 0.91 | CA1 (0.52) | PTPRCPTPN1MEN1KMT2ACDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118834119-A | Method for synthesizing bisphenol compound by catalysis of supported ionic liquid | 郑州中科新兴产业技术研究院 | 2024-10-25 | — | — | CN | claimed |
| CN-111885914-A | Compositions and methods for producing expanded hematopoietic stem cells using fluorene derivatives | 投资健康有限责任公司 | 2020-11-03 | — | — | CN | claimed |
| EP-3700334-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | Transfusion Health, LLC (US) | 2020-09-02 | — | — | EP | claimed |
| US-20200255371-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | IMMUNEBRIDGE LLC | 2020-08-13 | — | — | US | claimed |
| US-6368778-B1 | FLUORENONE, FLUORENE, COUMARIN, NAPHTHALIC ACID IMIDE, PYRAZOLINE, OR ANTHRACENE IMAGE STABILIZER COMPOUNDS IN THE SILVER LAYER REDUCE IMAGE BROWNING; STABLE TO LIGHT AND HEAT OVER TIME PARTICULARLY UNDER LIGHT-BOX CONDITIONS | EASTMAN KODAK COMPANY | 2002-04-09 | — | — | US | claimed |
| US-5914431-A | Cocatalysts for the synthesis of bisphenols | BAYER AG (DE) | 1999-06-22 | — | — | US | claimed |
| CN-122056781-A | Two-part dental sealant, method of administration with a syringe device, and kit | 舒万诺知识产权公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-3700334-B1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | IMMUNEBRIDGE INC (US) | 2026-04-08 | — | — | EP | disclosed |
| EP-4514304-B1 | DENTAL COMPOSITION CONTAINING A RESORCINOL OR CATECHOL MOIETY CONTAINING COMPONENT AND USE THEREOF | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12577340-B2 | Storage stable two-component dual cure dental composition | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4629958-A1 | SURFACE-TREATED FILLER, DENTAL COMPOSITION CONTAINING SUCH A FILLER, PROCESS OF PRODUCTION AND USE THEREOF | Solventum Intellectual Properties Company (US) | 2025-10-15 | — | — | EP | disclosed |
| EP-3880156-B1 | STORAGE STABLE TWO-COMPONENT DUAL CURE DENTAL COMPOSITION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12311037-B2 | Dental composition containing a resorcinol or catechol moiety containing component and use thereof | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY (US) | 2025-05-27 | — | — | US | disclosed |
| US-4735632-A | RAPID AND DEEP CURE OF BINDER OF MONOMER, ARYLIDONIUM SALT, SENSITIZER, AND ELECTRON DONOR | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1988-04-05 | — | — | US | disclosed |
| US-4540700-A | Treatment of diabetic complications with certain spiro-imidazolidine-diones | ALCON LABORATORIES, INC. (US) | 1985-09-10 | — | — | US | disclosed |
| US-4537892-A | ANTIDIABETIC AGENTS | ALCON LABORATORIES, INC. (US) | 1985-08-27 | — | — | US | disclosed |
| US-4438272-A | COMPLICATIONS OF DIABETES | ALCON LABORATORIES, INC. (US) | 1984-03-20 | — | — | US | disclosed |
| US-4436745-A | TETRACYCLIC SPIROHYDANTOINS | ALCON LABORATORIES, INC. (US) | 1984-03-13 | — | — | US | disclosed |
| WO-1983003543-A1 | METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS | ALCON LAB INC (US) | 1983-10-27 | — | — | WO | disclosed |
| EP-0092385-A2 | Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds | ALCON LABORATORIES, INC. (US) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12311037-B2 | Dental composition containing a resorcinol or catechol moiety containing component and use thereof | RDX, RECQL, RHOC | PTPRC 4232/4885PTPN1 4363/4885MEN1 3966/4885 |
| US-20200255371-A1 | COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE | FLI1, MCL1, HCLS1 | PTPRC 1353/4885PTPN1 2109/4885MEN1 1060/4885 |
| US-12577340-B2 | Storage stable two-component dual cure dental composition | GPX4, SSRP1, H1-0 | PTPRC 2425/4885PTPN1 3305/4885MEN1 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.